Navigation Links
Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million

- Two-Year Contract from the Defense Threat Reduction Agency Will Fund the Advanced Development of Cethromycin as a Potential Broad-Spectrum Medical

Countermeasure -

CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense has awarded the Company a two-year contract worth up to $3.8 million to further study cethromycin as a potential broad-spectrum medical countermeasure. The contract, part of the agency's Transformational Medical Technologies Initiative (TMTI), will fund NDA-enabling studies evaluating cethromycin's efficacy in combating Category A and B bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis).


"We are very excited to partner with DTRA and share its mission to reduce the threat of biological warfare and bioterrorism," stated Dr. Michael T. Flavin, chairman and chief executive officer of Advanced Life Sciences. "We believe this government contract further validates the potential of cethromycin as a biodefense agent, and it enables us to conduct pivotal studies to expand cethromycin's potential spectrum of activity beyond the success that was demonstrated in preventing inhalation anthrax."

Dr. Herbert Schweizer, Professor and Associate Program Director, Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research, Colorado State University stated, "Our initial evaluation of cethromycin against Burkholderia pseudomallei shows that it is very active and may have a more favorable resistance profile than other approved antibiotics in treating melioidosis." Dr. Schweizer added, "This government funding from DTRA for the advanced development of cethromycin to treat bioterror pathogens serves as a critical step that may result in advances for both national security and public health."

Under the terms of the contract, $1.8 million of DTRA funds are available over a nine-month base period to initiate NDA-enabling studies measuring cethromycin's efficacy in treating tularemia and plague as well as studies to measure cethromycin's efficacy in treating melioidosis. The remaining $2.0 million may be awarded over the ensuing 15 months to complete the project.

Dr. Michael Flavin went on to say, "The U.S. Government is committed to identifying and acquiring a next-generation antibiotic that has activity against more that one Category A and B bioterror pathogen. If cethromycin can demonstrate potent activity through the studies funded by this contract, we believe it will be well positioned to compete for revenues from a potential stockpile contract."

About the Defense Threat Reduction Agency

The Defense Threat Reduction Agency (DTRA) is the intellectual, technical and operational leader for the Department of Defense (DoD) and the U.S. Strategic Command in the national effort to combat the weapons of mass destruction (WMD) threat. Under DTRA, DoD resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threat. DTRA performs four essential functions to accomplish its mission: combat support, technology development, threat control and threat reduction. These functions form the basis for how it is organized and its daily activities.

About Cethromycin

Cethromycin is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired pneumonia (CAP). In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. In May of 2007, cethromycin completed a non-human primate study in which it was determined that a 30-day course of oral cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(R) (ciprofloxacin), which demonstrated 90% protection. The FDA has designated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post-exposure, but the FDA has not yet approved the drug for marketing in this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. For more information, please visit us on the web at

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Life Sciences To Host 2008 Second Quarter Financial Results Conference Call and Webcast
2. Advanced Bionics Reaches Resolution With FDA, Settles Financial Suit
3. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
4. Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy
5. Advanced Life Sciences Announces Collaboration With UK Ministry of Defence on ALS-886
6. U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security
7. Video: New, Advanced Therapy Program Helps People Who Stutter Acquire Fluent Speech
8. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
9. Advanced Life Sciences Added to Russell Microcap Index
10. Culligan's New Aqua-Cleer Advanced Drinking Water SystemProvides Clean, Quality Water Customized for Every Home
11. SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):